Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

NCT00694785 is registered in ClinicalTrials.gov with Archemix Corp. as lead sponsor.

NCT NCT00694785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00694785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
Lead sponsor
Archemix Corp.
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2008
Completion date
Not reported
Enrollment
2 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease